Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Bimatoprost (lashes) vs PT-141: they're closely matched on evidence (8 vs 5/10); they work on different things and are often used together, not either/or. Take the 60-second quiz for a pick tailored to your goals.
Bimatoprost (lashes) and PT-141 are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Bimatoprost (lashes) and PT-141 have evidence — compare verdict strength side-by-side.
Prescription topical. Bimatoprost 0.03% is applied once daily as a thin line to the skin of the UPPER eyelid margin at the lash base (not to the lower lid, and avoid getting it in the eye), using a fresh applicator per eye. Continuous use is needed to maintain results. Use under a clinician, especially if you have glaucoma or take prostaglandin eye drops. There is no oral or systemic use. This library does not provide an ingestion protocol.
evening
Bimatoprost 0.03% solution (Latisse) with single-use applicators, under a clinician
Approved (Vyleesi): 1.75 mg subcutaneous, self-injected on-demand ~45 min before anticipated sexual activity; max 1 dose/24 h and 8 doses/month
on-demand
Subcutaneous auto-injector (Vyleesi)
Throughout
8-16 weeks
2-6 months after stopping
Weeks to months
On-demand (per dose); endpoints assessed over 24 weeks
Throughout
Within hours of dosing
0-4 h post-dose
Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
Br J Dermatol (2015) · Rct
1-year double-masked RCT: composite primary endpoint (Global Eyelash Assessment + satisfaction) met for bimatoprost vs vehicle in idiopathic (40.2% vs 6.8%) and post-chemotherapy (37.5% vs 18.2%) hypotrichosis
Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
Aesthetic Plast Surg (2014) · Rct · n=209
Two double-masked vehicle-controlled RCTs (n=209: 173 idiopathic, 36 chemotherapy-induced) in Japanese subjects
The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.
Front Med (Lausanne) (2023) · Meta analysis
Meta-analysis of six placebo-controlled RCTs of topical prostaglandin analogs (incl. bimatoprost) for hair growth (lashes, brows, scalp)
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Obstet Gynecol (2019) · Rct · n=1267
Two identical phase-3, randomized, double-blind, placebo-controlled, multicenter trials (RECONNECT) of bremelanotide 1.75 mg subcutaneously as-needed over 24 weeks
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.
Obstet Gynecol (2019) · Open label · n=684
52-week open-label extension of the RECONNECT phase-3 program
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
J Sex Med (2019) · Rct
Phase-2b, randomized, controlled dose-ranging study in premenopausal women with HSDD and mixed HSDD/FSAD
Both Bimatoprost (lashes) and PT-141 are closely matched — the best choice depends on your specific health goals.
No known interactions between Bimatoprost (lashes) and PT-141 have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.